FDA Eases Rules on Drug Manufacturing
“Drug makers will not need regulatory approval for every change in their manufacturing processes under new guidelines designed to prevent supply disruptions, U.S. health officials said on Wednesday.
…
The modification is part of a just-completed, two-year effort to overhaul regulation of pharmaceutical manufacturing, a major issue for drug makers. “
Online Extra: “It’s a Perfect Storm” for Drugmakers: “Glaxo CEO Jean-Pierre Garnier on the industry’s hardships and how his company is improving its search for new drugs “
It’s a Perfect Storm” for Drugmakers
“Glaxo CEO Jean-Pierre Garnier on the industry’s hardships and how his company is improving its search for new drugs “
Long Trip for Psychedelic Drugs
“Psychedelic drugs are inching their way slowly but surely toward prescription status in the United States, thanks to a group of persistent scientists who believe drugs like ecstasy and psilocybin can help people with terminal cancer, obsessive-compulsive disorder and post-traumatic stress disorder, to name just a few. “
Genetically altered grass spreads like wildfire
“A new study shows that genes from genetically engineered grass can spread much farther than previously known, a finding that raises questions about the straying of other plants altered through biotechnology. That could hurt the efforts of two companies to win approval for the first bioengineered grass”
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments